X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (107) 107
oncology (101) 101
index medicus (94) 94
female (66) 66
chemotherapy (62) 62
cancer (61) 61
male (59) 59
middle aged (58) 58
aged (56) 56
colorectal cancer (39) 39
adult (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
care and treatment (28) 28
medicine & public health (27) 27
treatment outcome (27) 27
metastasis (25) 25
colorectal neoplasms - drug therapy (24) 24
research (24) 24
tumors (23) 23
animals (22) 22
cancer therapies (22) 22
aged, 80 and over (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
colorectal neoplasms - pathology (21) 21
cancer research (20) 20
gene expression (20) 20
s-1 (20) 20
fluorouracil (19) 19
survival (18) 18
analysis (17) 17
cell line, tumor (17) 17
expression (17) 17
gastric cancer (17) 17
irinotecan (17) 17
antimitotic agents (16) 16
antineoplastic agents (16) 16
clinical trials (16) 16
disease-free survival (16) 16
health aspects (16) 16
stomach cancer (16) 16
stomach neoplasms - drug therapy (16) 16
therapy (16) 16
antineoplastic agents - therapeutic use (15) 15
capecitabine (15) 15
fluorouracil - administration & dosage (15) 15
neoplasm metastasis (15) 15
oxaliplatin (15) 15
stem cells (15) 15
adenocarcinoma - drug therapy (14) 14
camptothecin - analogs & derivatives (14) 14
cisplatin (14) 14
deoxycytidine - analogs & derivatives (14) 14
drug administration schedule (14) 14
drug combinations (14) 14
japan (14) 14
oncology, experimental (14) 14
studies (14) 14
trial (14) 14
apoptosis (13) 13
cancer patients (13) 13
medical colleges (13) 13
mice (13) 13
mutation (13) 13
original (13) 13
pancreatic cancer (13) 13
pharmacology & pharmacy (13) 13
surgical oncology (13) 13
cetuximab (12) 12
drug therapy (12) 12
metabolism (12) 12
neoplasm staging (12) 12
organoplatinum compounds - administration & dosage (12) 12
oxonic acid - administration & dosage (12) 12
patients (12) 12
prognosis (12) 12
proteins (12) 12
tegafur - administration & dosage (12) 12
1st-line treatment (11) 11
antineoplastic agents - adverse effects (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
bevacizumab (11) 11
development and progression (11) 11
esophageal cancer (11) 11
fluorouracil - analogs & derivatives (11) 11
survival rate (11) 11
5-fluorouracil (10) 10
adenocarcinoma - mortality (10) 10
articles (10) 10
camptothecin - administration & dosage (10) 10
gastroenterology & hepatology (10) 10
leucovorin (10) 10
medical prognosis (10) 10
original article (10) 10
pharmacology/toxicology (10) 10
supportive care (10) 10
surgery (10) 10
adenocarcinoma (9) 9
cell lung-cancer (9) 9
cisplatin - administration & dosage (9) 9
deoxycytidine - administration & dosage (9) 9
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (282) 282
Japanese (12) 12
French (2) 2
Chinese (1) 1
German (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 687 - 697
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 631 - 639
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Journal Article
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 01/2015, Volume 42, Issue 1, pp. 12 - 15
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 01/2015, Volume 42, Issue 1, p. 12
It is expected that incidence of gastrointestinal cancers in elderly would increase. However limited data for chemotherapy is available for such patients.... 
Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Aged, 80 and over | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Aged | Practice Guidelines as Topic
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 11/2014, Volume 41, Issue 11, pp. 1372 - 1375
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Gastric Cancer, ISSN 1436-3291, 10/2015, Volume 18, Issue 4, pp. 824 - 832
This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone... 
Irinotecan | Anti-EGFR | Medicine & Public Health | Gastroenterology | Second-line therapy | Abdominal Surgery | Oncology | Cancer Research | Surgical Oncology | Advanced gastric cancer | Nimotuzumab | ADVANCED ESOPHAGOGASTRIC CANCER | MONOCLONAL-ANTIBODY H-R3 | CHEMOTHERAPY PLUS | CELL LUNG-CANCER | CAPECITABINE | GROWTH-FACTOR RECEPTOR | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | EGFR ANTIBODY | 1ST-LINE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Antibodies, Monoclonal, Humanized - administration & dosage | DNA Mutational Analysis | Polymerase Chain Reaction | Adult | Camptothecin - administration & dosage | Female | Adenocarcinoma - genetics | Camptothecin - analogs & derivatives | Genes, ras - genetics | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Receptor, Epidermal Growth Factor - biosynthesis | Receptor, ErbB-2 - biosynthesis | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Stomach Neoplasms - mortality | Salvage Therapy - methods | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Cancer patients | Clinical trials | Product development | Antineoplastic agents | Stomach cancer | Cancer | Original
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
Gastric Cancer, ISSN 1436-3291, 7/2012, Volume 15, Issue 3, pp. 313 - 322
The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2)... 
Pathology | Medicine & Public Health | Gastroenterology | Oncology | Radiotherapy | Drug therapy | Surgical Oncology | Randomized controlled trial | Trastuzumab | Stomach neoplasms | CAPECITABINE | THERAPY | CISPLATIN | ONCOLOGY | PHASE-III | GASTROENTEROLOGY & HEPATOLOGY | CHEMOTHERAPY | Prognosis | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Stomach Neoplasms - metabolism | Male | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Esophageal Neoplasms - metabolism | Aged, 80 and over | Esophageal Neoplasms - mortality | Adult | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Proportional Hazards Models | Survival Rate | Stomach Neoplasms - drug therapy | Asian Continental Ancestry Group | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Medical colleges | Oncology, Experimental | College teachers | Metastasis | Research | Stomach cancer | Biometry | Chemotherapy | Epidermal growth factor | Analysis | Cross infection | Diabetes | Kidney diseases | Nosocomial infections | Public health | Cancer | Fluorouracil | Original
Journal Article